Loading data for ATYR — first visit, this takes a few seconds.
aTyr Pharma Inc. (ATYR)
NasdaqCM: ATYR
· Real-Time Price · USD
0.50
+0.00 (0.00%)
At close: Aug 21, 2026, 8:00 PM
0.53
+4.69%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
aTyr Pharma Inc. (ATYR) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 0.37 |
| Market Cap | 49.19M |
| Revenue (ttm) | 190K |
| Net Income (ttm) | -60.81M |
| 0.52 | |
| -0.63 | |
| n/a | |
| -1.08 | |
| P/B (ttm) | 1.01 |
| P/S (ttm) | 258.90 |
| Earnings Date | Nov 5, 2026 |
| Ask | 0.66 |
| Volume | 481,012 |
| Avg. Volume (20D) | 1,776,645 |
| Open | 0.51 |
| Previous Close | 0.50 |
| Day's Range | 0.50 - 0.53 |
| 52-Week Range | 0.40 - 6.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2015
Employees 58
Stock Exchange NasdaqCM
Ticker Symbol ATYR
Website https://atyrpharma.com
Financial Performance
In 2025, aTyr Pharma's revenue was 190K, a decrease of -19.15% compared to the previous year's 235K. Earnings were -74.12M, an increase of 15.77%.
Financial StatementsEarnings Surprise
aTyr Pharma has released their quarterly earnings on Aug 7, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.11 exceeds estimates by 0.01, with 50.00% YoY growth.
aTyr Pharma Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2